CareDx (NASDAQ:CDNA) Director Sells $1,092,270.00 in Stock

CareDx, Inc. (NASDAQ:CDNA – Get Free Report) Director Michael Goldberg sold 13,800 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $79.15, for a total value of $1,092,270.00. Following the completion of the transaction, the director owned 48,526 shares of the company’s stock, valued at $3,840,832.90. This represents a 22.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CareDx Stock Performance

NASDAQ:CDNA opened at $74.44 on Thursday. The stock has a fifty day moving average price of $67.77 and a 200-day moving average price of $37.51. The company has a market cap of $3.91 billion, a price-to-earnings ratio of 31.15 and a beta of 2.51. CareDx, Inc. has a fifty-two week low of $15.56 and a fifty-two week high of $90.87.

CareDx (NASDAQ:CDNA – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45. The firm had revenue of $139.36 million for the quarter, compared to the consensus estimate of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The company’s revenue was up 39.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 EPS. Research analysts predict that CareDx, Inc. will post 1.00 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Monday, August 3rd. Wall Street Zen lowered shares of CareDx from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 31st. BTIG Research boosted their price objective on CareDx from $81.00 to $92.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Zacks Research raised shares of CareDx from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 5th. Finally, Canaccord Genuity Group set a $99.00 price objective on CareDx in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, CareDx has an average rating of “Moderate Buy” and a consensus target price of $70.33.

View Our Latest Stock Report on CareDx

Hedge Funds Weigh In On CareDx

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in CareDx in the 2nd quarter valued at about $137,219,000. Bamco Inc. NY acquired a new stake in CareDx in the 2nd quarter worth approximately $55,214,000. Bank of America Corp DE acquired a new position in shares of CareDx in the second quarter valued at $16,297,000. Palo Alto Investors LP acquired a new position in shares of CareDx during the second quarter worth approximately $15,158,295. Finally, Jupiter Topco LLC acquired a new stake in shares of CareDx during the second quarter worth about $9,673,000.

CareDx Company Profile

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

See Also

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.